Company intelligence / Profile preview

Sibionics

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Sibionics' GS1 Continuous Glucose Monitoring (CGM) system is CE-marked and approved in China and the UAE for diabetes management, and used by over 1,000,000 users globally. Their AI-Aided Fundus Screening is approved for clinical use in China for diabetic retinopathy and other retinal diseases. The company is recognized as a leading innovator in integrating biosensors and artificial intelligence for chronic disease management.

Therapeutic areas: OtherOncologyOphthalmologyEndocrinology
Modalities: DeviceArtificial intelligence
Industry: Physiological Monitoring

Partnerships

PharmaSens AG (for all-in-one integrated insulin delivery and glucose sensing patch pump)

Beyond the preview

Go deeper on Sibionics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sibionics.

Explore the full profile